Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Park et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69d937bcc7f0c3ae80a3c4e5 — DOI: https://doi.org/10.1200/jco.23.01891

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer· 2016 · 80 citations
2. Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer· 2017 · 2,434 citations
3. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722· 2022 · 49 citations
4. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma· 2016 · 707 citations
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,261 citations